Overview

Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
0
Participant gender:
Male
Summary
The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Radboud University
Treatments:
Caffeine
Dipyridamole
Criteria
Inclusion Criteria:

- Male

- Age between 18-50yr.

Exclusion Criteria:

- cardiovascular disease

- hypertension (systole > 140 mmHg, diastole > 90 mmHg)

- hypercholesterolemia (random total cholesterol > 6.5 mmol/l)

- diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)

- asthma (recurrent episodes of dyspnea and wheezing, or usage of prescribed inhalation
medication: i.e. corticosteroids or B2-agonists)

- participation in any clinical trial during the last 60 days prior to this study.

- administration of two doses of Annexin A5 (0,1mg; 450MBq) during the last 5 years
prior to this study.